Table 1 The details included studies

Gulseren Aktas

2005 and 2007

2010

7

Turkey

clinical isolates

237

Dalbavancin

 ≤ 0.008 / 0.25

 ≤ 0.008–2

99.6

[44]

Gulseren Aktas

2014 and 2015

2016

7

Turkey

clinical isolates

30

Dalbavancin

0.12 / 0.12

0.03–0.12

100

[45]

Maya Azrad

2015 and 2017

2019

7

Israel

Blood sample, Wounds

275

Tedizolid

0.25 / 0.3

0.19–0.5

100

[46]

275

Dalbavancin

MIC50: 0.047 / MIC90:0.055 (wound)/0.06 (Blood sample)

0.023–0.19

99.64

[46]

Diane M. Citron

No data

2014

6

USA

osteomyelitis

15

Dalbavancin

0.06 /0.06

 ≤ 0.03–0.12

No data

[47]

G. Ralph Corey

2011 to 2013

2016

7

USA

blood culture and ABSSSI

405

Oritavancin

0.03 / 0.12

0.002–0.25

99.1

[48]

Ko-Hung Chen

2013 to 2014

2015

7

Taiwan

ABSSSI and pneumonia

ABSSSI (50) and pneumonia (50)

Tedizolid

ABSSSI (0.25/0.25) and pneumonia (0.5/0.5)

ABSSSI (0.25/0.5) and pneumonia (0.25/0.5)

ABSSSI (100) and pneumonia (100)

[21]

Yong Pil Chong

2004 to 2009

2012

Korea

blood cultures

569

Dalbavancin

0.25 / 0.25

0.06–0.25

98.8

[49]

Aneta Guzek

2012 to 2014

2018

7

Poland

clinical isolates

124

Dalbavancin

0.094/0.125

0.032–0.125

100

[50]

Vanthida Huang

No data

2010

7

USA

220 clinical isolates

CA-MRSA (110), MDR HA-MRSA (n = 110)

Dalbavancin

CA-MRSA: 0.0625/0.125, MDR HA-MRSA: 0.125/0.125

CA-MRSA (0.0625–0.125), MDR HA-MRSA (0.03125–0.25)

No data

[51]

Ronald N. Jones

2011–2014

2017

7

North American, Latin American, European, and Asia–Pacific Nations

bone and joint

229

Telavancin

0.03 / 0.06

 ≤ 0.015–0.06

100

[52]

James A. Karlowsky

2014 to 2016

2017

7

Asia/Pacific region (Australia [n = 2], China [n = 16], New Zealand [n = 2], Philippines [n = 2], Taiwan [n = 2]), the Latin America region (Argentina [n = 2], Brazil [n = 10], Chile [n = 2], Colombia [n = 2], Mexico [n = 6]), Russia (n = 7), and Saudi Arabia (n = 1)

ABSSSI, blood samples, respiratory infections

1839

Tedizolid

0.25 / 0.5

0.03–0.5

100

[53]

Yangsoon Lee

2011 to 2014

2015

7

Korea

SSSIs, HAP

skin and skin structure infections (90), hospital-acquired pneumonia (61)

Tedizolid

skin and skin structure infections (0.5 / 0.5), hospital-acquired pneumonia (0.25/ 0.5)

skin and skin structure infections (0.125–0.5), hospital-acquired pneumonia (0.125–0.5)

100

[54]

María Carmen López-Díaz

2012 to 2014

2017

7

Spain

clinical isolates

55

Dalbavancin

0.125 / 0.125

0.06–0.125

100

[55]

Johanna Marcela Vanegas Múnera

2008 to 2010

2017

7

Colombia

clinical isolates

150

Tedizolid

0.38 / 0.5

 ≤ 0.19–0.75

100

[56]

Rodrigo E. Mendes

2011 to 2013

2015

7

USA

clinical isolates

4651

Telavancin

0.03 / 0.06

 ≤ 0.015–0.12

100

[57]

Sandra P. McCurdy

2002–2012

2015

7

USA, Europa, Russian and Israeli

clinical isolates

26975

Dalbavancin

0.06 / 0.06

 < 0.008–0.5

99.6

[58]

R. E. Mendes

2011–2014

2017

7

North America (2150 isolates), Europe (1283), Latin America (473), and Asia–Pacific (APAC; 285) regions

blood samples

1490

Telavancin

0.03 / 0.06

 ≤ 0.015–0.12

100

[59]

Jessica Baleiro Okado

2011- 2012

2018

7

Brazil

clinical isolates

27

Tedizolid

0.25 / 0.25

0.125–0.5

100

[60]

Michael A. Pfaller

2014–2015

2019

7

USA

SSSIs, bacteremia, pneumonia, intra-abdominal infections, urinary tract infections

1732

Tedizolid

0.12 / 0.12

0.03–0.25

100

[61]

Philippe Prokocimer

2008–2009

2012

7

USA

clinical isolates

124

Tedizolid

0.25 / 0.25

0.12–0.5

100

[62]

Kenneth VI Rolston

2012–2013

2014

7

USA

clinical isolates

50

Telavancin

0.25 / 0.25

0.064–0.38

No data

[63]

Laser Sanal

2013–2016

2018

7

Turkey

blood and tracheal aspirate

50

Telavancin

0.032 / 0.064

0.016—0.125

100

[64]

Suzannah M. Schmidt-Malan

1996–2014

2016

7

USA

clinical isolates

35

Tedizolid

0.5 / 0.5

0.25–0.5

100

[65]

Wael Shams

1991–2006

2010

7

USA

bloodstream, respiratory tract and wound

168

Telavancin

0.25 / 0.50

0.08–1.00

No data

[66]

Debora Sweeney

2017

7

USA

clinical isolates

15

Oritavancin

0.06 / 0.12

0.03–0.12

100

[67]

Dalbavancin

0.03 / 0.06

0.03–0.06

100

[67]

Telavancin

0.06 / 0.06

0.06–0.12

100

[67]

Tedizolid

0.25 / 0.5

0.25–0.5

100

[67]

Jennifer I. Smart

No data (2008)

2016

7

USA

SSSIs

700

Telavancin

0.06/0.06

0.03–0.12

100

[68]

Kenneth S. Thomson

No data

2013

7

USA

clinical isolates

111

Tedizolid

0.5 / 0.5

0.12–0.5

100

[69]

Floriana Campanile

2005–2007

2010

7

Italia

bloodstream, pneumonia, and SSSIs

24

Dalbavancin

0.06 / 0.12

0.03–0.12

100

[70]

D. J. Biedenbach

2013–2014

2016

7

Argentina, Brazil, Chile, Mexico, Australia and New Zealand, china

clinical isolates

Argentina, Brazil, Chile, and Mexico (318), Australia and New Zealand (51) china (425)

Tedizolid

Argentina, Brazil, Chile,and Mexico (0.5/0.5), Australia and New Zealand (0.25 / 0.5), china (0.25 / 0.5)

0.12–0.5

100

[39]

Carmen Betriu

2004–2008

2010

7

Spain

Blood samples

247

Tedizolid

0.25/0.5

0.125–0.5

100

[40]

Mekki Bensaci

2009–2013

2017

7

USA

clinical isolates

3234

Tedizolid

0.25/0.5

 ≤ 0.015 to 2

99.6

[71]

Hongbin Chen

2009–2013

2014

7

China

SSSIs, lower respiratory tract infections

100

Tedizolid

0.25 / 0.25

0.064–1

No data

[72]

Steven D. Brown

No data

2010

7

USA

clinical isolates

129

Tedizolid

0.5 /1

0.12–16

No data

[73]

Jong Hwa Yum

2002–2004

2010

7

South Korea

clinical isolates

30

Torezolid

0.5/0.5

0.5

100

[74]

Daniel F. Sahm

2011–2012

2015

7

USA, Europa

clinical isolates

1770

Tedizolid

0.25/0.5

0.015–4

99.7

[75]

Shuguang Li

2014

2016

7

China

clinical isolates

632

Tedizolid

0.25 / 0.25

0.064–0.5

100

[76]

Marina Peñuelas

No data

2016

7

Spain

clinical isolates

18

Tedizolid

0.25/0.5

0.125–0.5

100

[77]

Michael A. Pfaller

2014

2016

7

Asia–Pacific, Eastern Europe, and Latin American Countries

clinical isolates

701

Tedizolid

0.12/0.12

0.03–0.25

100

[78]